Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Park West Asset Management and PLX Pharma Inc. (PLXP)

PLX Pharma Inc. (NASDAQ:PLXP): Peter S. Park’s Park West Asset Management filed an amended 13D.

You can check out Park West Asset Management’s latest holdings and filings here.

Please follow Park West Asset Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Park West Asset Management or update its stock holdings.

Peter S. Park
Peter S. Park
Park West Asset Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Park West Asset Management 0 1,075,723 0 1,075,723 1,075,723 12.3%
Park West Investors Master Fund, Limited 0 953,465 0 953,465 953,465 10.9%
Peter S. Park 0 1,075,723 0 1,075,723 1,075,723 12.3%
Peter S. Park
Peter S. Park
Park West Asset Management

Page 1 of 10 – SEC Filing

 

UNITED STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
DC 20549

 

SCHEDULE 13D

THE SECURITIES
EXCHANGE ACT OF 1934

(Amendment No.  )*

 

 

PLx
Pharma Inc.
(Name of Issuer)

  

Common
Stock, $0.001 par value per share
(Title of Class of
Securities)

  

72942A107
(CUSIP Number)

  

Grace
Jimenez

c/o Park
West Asset Management LLC

900 Larkspur
Landing Circle, Suite 165

Larkspur,
CA 94939

Telephone
Number: (415) 524-2900

(Name,
Address and Telephone Number of Person Authorized to Receive

Notices
and Communications)

  

November
20, 2017
(Date of Event Which
Requires Filing of this Statement)

 

 

If the filing person has previously
filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  [x].
   
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

 

 

Follow Plx Pharma Inc. (NASDAQ:PLXP)
Trade (NASDAQ:PLXP) Now!
Loading...